These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9871434)

  • 1. Dopamine-glutamate interactions in the basal ganglia.
    Schmidt WJ
    Amino Acids; 1998; 14(1-3):5-10. PubMed ID: 9871434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical neuroanatomy of the basal ganglia--normal and in Parkinson's disease.
    Hornykiewicz O
    J Chem Neuroanat; 2001 Jul; 22(1-2):3-12. PubMed ID: 11470551
    [No Abstract]   [Full Text] [Related]  

  • 3. Glutamatergic influences on the basal ganglia.
    Greenamyre JT
    Clin Neuropharmacol; 2001; 24(2):65-70. PubMed ID: 11307040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progresses in the study of unbalance of basal ganglia neurotransmitters in Parkinson's disease].
    Sun ZL; Jia J; Yu F
    Sheng Li Ke Xue Jin Zhan; 2011 Dec; 42(6):427-30. PubMed ID: 22363981
    [No Abstract]   [Full Text] [Related]  

  • 5. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.
    Sgambato-Faure V; Cenci MA
    Prog Neurobiol; 2012 Jan; 96(1):69-86. PubMed ID: 22075179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balance of transmitter activities in the basal ganglia loops.
    Schmidt WJ
    J Neural Transm Suppl; 1995; 46():67-76. PubMed ID: 8821042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease.
    Starr MS
    Synapse; 1995 Apr; 19(4):264-93. PubMed ID: 7792721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome.
    Gerlach M; Gsell W; Kornhuber J; Jellinger K; Krieger V; Pantucek F; Vock R; Riederer P
    Brain Res; 1996 Nov; 741(1-2):142-52. PubMed ID: 9001716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMDA receptors in the basal ganglia.
    Ravenscroft P; Brotchie J
    J Anat; 2000 May; 196 ( Pt 4)(Pt 4):577-85. PubMed ID: 10923988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term depression at distinct glutamatergic synapses in the basal ganglia.
    Dupuis JP; Bioulac BH; Baufreton J
    Rev Neurosci; 2014; 25(6):741-54. PubMed ID: 25046307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anatomy of the dopamine system in the basal ganglia.
    Smith Y; Kieval JZ
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S28-33. PubMed ID: 11052217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent.
    Cobb WS; Abercrombie ED
    Neuroscience; 2003; 119(3):777-86. PubMed ID: 12809698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia.
    Marino MJ; Awad H; Poisik O; Wittmann M; Conn PJ
    Amino Acids; 2002; 23(1-3):185-91. PubMed ID: 12373536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review.
    Jamwal S; Kumar P
    Curr Neuropharmacol; 2019; 17(2):165-175. PubMed ID: 29512464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects of glutamate antagonists in the therapy of Parkinson's disease.
    Blandini F; Greenamyre JT
    Fundam Clin Pharmacol; 1998; 12(1):4-12. PubMed ID: 9523179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralaminar thalamic nuclei lesions: widespread impact on dopamine denervation-mediated cellular defects in the rat basal ganglia.
    Bacci JJ; Kachidian P; Kerkerian-Le Goff L; Salin P
    J Neuropathol Exp Neurol; 2004 Jan; 63(1):20-31. PubMed ID: 14748558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease.
    Bezard E; Crossman AR; Gross CE; Brotchie JM
    FASEB J; 2001 Apr; 15(6):1092-4. PubMed ID: 11292678
    [No Abstract]   [Full Text] [Related]  

  • 18. Dopamine/glutamate interactions in Parkinson's disease.
    Lange KW; Kornhuber J; Riederer P
    Neurosci Biobehav Rev; 1997 Jul; 21(4):393-400. PubMed ID: 9195597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of surgery targeting the caudal intralaminar thalamic nuclei on the pathophysiological functioning of basal ganglia in a rat model of Parkinson's disease.
    Kerkerian-Le Goff L; Bacci JJ; Jouve L; Melon C; Salin P
    Brain Res Bull; 2009 Feb; 78(2-3):80-4. PubMed ID: 18790021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic, synaptic and behavioral impact of 5-week chronic deep brain stimulation in hemiparkinsonian rats.
    Chassain C; Melon C; Salin P; Vitale F; Couraud S; Durif F; Kerkerian-Le Goff L; Gubellini P
    J Neurochem; 2016 Mar; 136(5):1004-16. PubMed ID: 26576509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.